Archiv der Pharmazie最新文献

c-KIT Small Molecule Inhibitors as a Therapeutic Strategy for Melanoma: Clinical Insights, SAR, and Future Directions. c-KIT小分子抑制剂作为黑色素瘤的治疗策略：临床见解，SAR和未来方向。

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-10-01 DOI: 10.1002/ardp.70113

Shubham C Rivonker, Hossam Nada, Cho Jaemin, Yong-Jun Kwon, Kyeong Lee

引用次数: 0

Exploring the Antidiabetic Potential of Heterophylliin A From Elaeocarpus grandis. 巨腕树异茶碱A抗糖尿病作用的研究。

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-10-01 DOI: 10.1002/ardp.70110

Sherif A Maher, Radwa Taher Mohie El-Dien, Muhamad Mustafa, Amgad I M Khedr, Ahmed M Sayed, Usama Ramadan Abdelmohsen, Mostafa A Fouad, Mohamed Salah Kamel

{"title":"Exploring the Antidiabetic Potential of Heterophylliin A From Elaeocarpus grandis.","authors":"Sherif A Maher, Radwa Taher Mohie El-Dien, Muhamad Mustafa, Amgad I M Khedr, Ahmed M Sayed, Usama Ramadan Abdelmohsen, Mostafa A Fouad, Mohamed Salah Kamel","doi":"10.1002/ardp.70110","DOIUrl":"https://doi.org/10.1002/ardp.70110","url":null,"abstract":"<p><p>The antidiabetic efficacy of Elaeocarpus grandis, belonging to the Family Elaeocarpaceae, was investigated using the streptozotocin-induced hyperglycemia model. The ethyl acetate and petroleum ether fractions demonstrated a notable hypoglycemic impact in a rat model of type 2 diabetes mellitus (T2DM), compared to the negative control group. The chemical assessment of these fractions resulted in the isolation and identification of six known compounds (17-22). LC-HR-ESI-MS metabolomic profiling yielded the provisional identification of sixteen metabolites (1-16) across various chemical classes. In silico investigations, encompassing molecular docking and dynamics simulations, indicated that the compounds heterophylliin A (22), as well as habbemine A (12) and elaeocarpinoside (15), can interact with critical enzymes implicated in glucose metabolism, specifically dipeptidyl peptidase-IV and aldose reductase. Moreover, heterophylliin A (22) markedly decreased the expression of inflammatory markers (IL-1β, TNF-α, IL-6, and TGF-β) in diabetic rats. These findings prompt additional research on E. grandis, specifically its bioactive constituent heterophylliin A, which exhibits intriguing antidiabetic effects and warrants further exploration as a potential treatment agent for T2DM.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":"e70110"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibitory Effects of 3-Deoxysappanchalcone on Factor Xa Activity, Platelet Aggregation, and Experimentally Induced Thrombosis. 3-脱氧参查尔酮对Xa因子活性、血小板聚集和实验性血栓形成的抑制作用。

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-10-01 DOI: 10.1002/ardp.70101

Jinhee Lee, Gyuri Han, Jong-Sup Bae

{"title":"Inhibitory Effects of 3-Deoxysappanchalcone on Factor Xa Activity, Platelet Aggregation, and Experimentally Induced Thrombosis.","authors":"Jinhee Lee, Gyuri Han, Jong-Sup Bae","doi":"10.1002/ardp.70101","DOIUrl":"https://doi.org/10.1002/ardp.70101","url":null,"abstract":"<p><p>3-Deoxysappanchalcone (3-DSC), extracted from Caesalpinia sappan L., is recognized for its anti-inflammatory, anti-influenza, and anti-allergic effects, but its antithrombotic properties have not been investigated. This study explores whether 3-DSC exhibits antithrombotic effects and examines the mechanisms involved. The antithrombotic properties of 3-DSC were assessed through various methods, including tests for clotting times, platelet aggregation analysis, evaluation of factor Xa activity and production, nitric oxide levels, and the expression of related proteins. This study found that 3-DSC extended the clotting time in human platelet-poor plasma at levels comparable to rivaroxaban, a standard anticoagulant, and reduced platelet aggregation triggered by ADP or the thromboxane A2 analog U46619. Additionally, 3-DSC suppressed the phosphorylation of PLCγ2 and PKC, as well as intracellular calcium release, which are essential for platelet aggregation. It also decreased the expression of adhesion molecules P-selectin and PAC-1. Furthermore, 3-DSC promoted nitric oxide production while reducing endothelin-1 secretion in endothelial cells exposed to ADP or U46619. Lastly, it inhibited both the activity and production of coagulation factor Xa in endothelial cells and prevented activated factor X (FXa)-induced platelet aggregation. Injection of 3-DSC significantly shortened the time required for thrombus resolution, reduced the size and number of thrombi, and decreased mortality in mouse models of thromboembolism. The study demonstrates that 3-DSC effectively exhibits antithrombotic activity by prolonging the clotting time, inhibiting platelet aggregation, and reducing factor Xa activity, comparable to standard anticoagulants. These findings highlight the potential of 3-DSC as a promising therapeutic agent targeting multiple pathways involved in thrombosis, with reduced side effects.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":"e70101"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultra-Fast Green UPLC-MS/MS Method for the Quantification of Cediranib in the Human Liver Microsome Matrix: In Vitro and In Silico Metabolic Stability Assessment 超快速绿色超高效液相色谱-质谱联用法定量人肝微粒体基质中Cediranib的体外和计算机代谢稳定性评价

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-09-27 DOI: 10.1002/ardp.70111

Mohamed W. Attwa, Ali S. Abdelhameed, Adnan A. Kadi

{"title":"Ultra-Fast Green UPLC-MS/MS Method for the Quantification of Cediranib in the Human Liver Microsome Matrix: In Vitro and In Silico Metabolic Stability Assessment","authors":"Mohamed W. Attwa, Ali S. Abdelhameed, Adnan A. Kadi","doi":"10.1002/ardp.70111","DOIUrl":"https://doi.org/10.1002/ardp.70111","url":null,"abstract":"<div>\u0000 \u0000 <p>Cediranib (AZD2171; CDB) is an oral pan-VEGF receptor tyrosine kinase inhibitor and a potent antiangiogenic agent. This study sought to develop a precise, rapid, dependable, and sustainable UPLC-MS/MS approach for measuring CDB in the human liver microsome (HLM) matrix, utilized for assessing the CDB metabolic stability inside this matrix. The validation processes for the UPLC-MS/MS system adhered to US-FDA rules for bioanalytical technique validation. The validated method utilized the HLM matrix throughout a level range of 1–4000 ng/mL with a duration of 1 min on UPLC-MS/MS instrumentation. The precision (%RSD) and accuracy (%E) rates for intraday and interday measurements varied from −1.41% to 8.0% and from −2.75% to 9.67%, respectively. The StarDrop software employed P450 and DEREK modules to evaluate metabolic lability and to characterize CDB structural warnings, respectively. The in vitro <i>t</i><sub>1/2</sub> was determined to be 25.48 min, and the CDB intrinsic clearance was determined to be 31.82 mL/min/kg. In silico assessments indicate that slight structural modifications to the pyrrolidine moiety (61%), methyl group (32%), and the propyl group (7%) in drug design could increase the CDB metabolic stability. The assessment of in silico CDB ADME characteristics and metabolic stability is fundamental for progressing innovative drug research focused on augmenting metabolic stability.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Loading of Dicarboxylatoplatinum(II)-NHC Complexes in Bacterial Ghosts as an Advanced Development in Cancer Therapy 二羧基白铂(II)-NHC配合物在细菌幽灵中的负载作为癌症治疗的最新进展

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-09-27 DOI: 10.1002/ardp.70108

Amelie Scherfler, Klaus Wurst, Stefan Schwaiger, Francesco Baschieri, Martin Hermann, Daniel Baecker, Irena Pashkunova-Martic, Brigitte Kircher, Hristo P. Varbanov

{"title":"Loading of Dicarboxylatoplatinum(II)-NHC Complexes in Bacterial Ghosts as an Advanced Development in Cancer Therapy","authors":"Amelie Scherfler, Klaus Wurst, Stefan Schwaiger, Francesco Baschieri, Martin Hermann, Daniel Baecker, Irena Pashkunova-Martic, Brigitte Kircher, Hristo P. Varbanov","doi":"10.1002/ardp.70108","DOIUrl":"https://doi.org/10.1002/ardp.70108","url":null,"abstract":"<p>This study aimed to improve the drug-like properties of benzimidazole-based Pt(II)-N-heterocyclic carbene (NHC) complexes, particularly by enhancing their water solubility and delivery to cancer cells. Accordingly, four new Pt(II) complexes of the benzimidazol-2-ylidene type, featuring monodentate carboxylato ligands, were prepared and their structures confirmed through a combination of spectroscopic and crystallographic techniques. Their stability in aqueous solution and cell culture medium was investigated by <sup>1</sup>H NMR spectroscopy and HPLC-MS analysis. Cytotoxicity was assessed using the MTT assay in ovarian cancer cell lines (A2780wt (cisplatin sensitive) and A2780cis (cisplatin resistant)) and a noncancerous bone marrow stromal cell line (HS-5). Most complexes exhibited cytotoxicity comparable to or exceeding that of carboplatin, with preferential activity toward cancer cells. Loading of all four Pt(II) complexes into bacterial ghost cells (BGs) derived from two different nonpathogenic bacterial strains, <i>Escherichia coli (E. coli)</i> Nissle 1917 and <i>E. coli</i> NM522 notably enhanced the intracellular accumulation and cytotoxicity. Furthermore, mechanistic studies demonstrated that all tested compounds, regardless of formulation, induced apoptosis. Their potential to trigger immunogenic cell death was also evaluated, though only a modest effect was observed on selected hallmarks. Collectively, these findings highlight the potential of dicarboxylatoplatinum(II)-NHC complexes, particularly loaded into BG-based formulations, as promising anticancer drug candidates.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70108","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Structural Advances in Non-Sulfonamide Carbonic Anhydrase Inhibitors: Insights Into Design, Bioactivity, and Binding Mechanism 非磺胺碳酸酐酶抑制剂的结构进展：设计、生物活性和结合机制的见解。

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-09-23 DOI: 10.1002/ardp.70090

Mahmood Ahmed, Muhammad Zaeem Mehdi, Mehwish Javed, Mohammed H. AL Mughram, Masooma Irfan, Ahmad Saeed, Ali Abbas Aslam

{"title":"Structural Advances in Non-Sulfonamide Carbonic Anhydrase Inhibitors: Insights Into Design, Bioactivity, and Binding Mechanism","authors":"Mahmood Ahmed, Muhammad Zaeem Mehdi, Mehwish Javed, Mohammed H. AL Mughram, Masooma Irfan, Ahmad Saeed, Ali Abbas Aslam","doi":"10.1002/ardp.70090","DOIUrl":"10.1002/ardp.70090","url":null,"abstract":"<div>\u0000 \u0000 <p>Carbonic anhydrases (CAs) belong to a set of metalloenzymes that facilitate the reversible catalytic hydration of CO<sub>2</sub>, playing crucial roles in pH regulation, respiration, and electrolyte secretion. Dysregulation of specific CA isoforms, particularly the human variants hCA I, II, IX, and XII, is implicated in multiple pathological conditions, including glaucoma, epilepsy, obesity, and various cancers. Traditionally, sulfonamide-based inhibitors have dominated the therapeutic landscape; however, their limitations, such as off-target side effects, poor selectivity for different isoforms, and allergic reactions, have galvanized interest in alternative scaffolds. This comprehensive review critically examines the burgeoning class of non-sulfonamide inhibitors targeting hCA isoforms, focusing on the chemical diversity, binding mechanisms, and structure–activity relationships of recently developed phenols, carboxylic acids, coumarins, dithiocarbamates, and polyamines. Special attention is given to the advances in X-ray crystallography and computational modeling that have illuminated binding modes distinct from classical sulfonamide interactions. By synthesizing the latest findings, this review aims to guide future efforts in the rational design of selective and efficacious non-sulfonamide CA inhibitors for clinical application.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145129646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medicinal Chemistry, SAR, and Molecular Insights Into 2,4-Thiazolidinediones as Antidiabetic Agents (2020–2025) 2,4-噻唑烷二酮类抗糖尿病药物的药物化学、SAR和分子研究（2020-2025）

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-09-22 DOI: 10.1002/ardp.70102

Neeru Malik, Rajesh Kumar Singh

{"title":"Medicinal Chemistry, SAR, and Molecular Insights Into 2,4-Thiazolidinediones as Antidiabetic Agents (2020–2025)","authors":"Neeru Malik, Rajesh Kumar Singh","doi":"10.1002/ardp.70102","DOIUrl":"https://doi.org/10.1002/ardp.70102","url":null,"abstract":"<div>\u0000 \u0000 <p>The thiazolidinedione (TZD) scaffold has long been recognized for its pharmacological versatility, particularly in the treatment of metabolic and inflammatory disorders. Among its derivatives, 2,4-thiazolidinediones (2,4-TZDs) have emerged as a prominent class of antidiabetic agents with diverse molecular targets. While their role as peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists is well established, recent studies have revealed additional therapeutic mechanisms, including inhibition of protein tyrosine phosphatase 1B (PTP-1B), α-amylase, α-glucosidase, and aldose reductase—each contributing to improved glucose regulation and diabetes management. Moreover, the rise of dual and multitarget inhibitors highlights the evolving therapeutic potential of 2,4-TZDs beyond conventional pathways. This review presents a comprehensive analysis of recent developments (2020–2025) in the medicinal chemistry, structure–activity relationships (SARs), and antidiabetic mechanisms of 2,4-TZDs. Key structural modifications and their influence on biological activity are critically evaluated, alongside updates on recent patent disclosures and ongoing clinical trials. By integrating medicinal chemistry insights with pharmacological data, this review aims to support the rational design of next-generation 2,4-TZD-based antidiabetic therapeutics.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI/ML-Driven DPP-4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps AI/ ml驱动的DPP-4抑制剂预测器（d4p_v1）用于增强2型糖尿病管理：对化学空间，指纹和静电电位图的见解

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-09-22 DOI: 10.1002/ardp.70106

Anu Manhas, Ritam Dutta, Stefano Piotto, Sk. Abdul Amin

{"title":"AI/ML-Driven DPP-4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps","authors":"Anu Manhas, Ritam Dutta, Stefano Piotto, Sk. Abdul Amin","doi":"10.1002/ardp.70106","DOIUrl":"https://doi.org/10.1002/ardp.70106","url":null,"abstract":"<p>Dipeptidyl peptidase-4 inhibitors (DPP-4i) represent a relatively new class of oral antidiabetic drugs. This study focuses on: (a) identifying favourable and unfavourable fingerprints governing DPP-4 inhibition using fragment-based analysis, (b) validating key fingerprints through HOMO–LUMO gap analysis and electrostatic potential (ESP) maps, and (c) developing AI/ML-driven DPP-4 predictor, an online cheminformatics tool for efficient DPP-4i screening using a trained, validated AI/ML model. The fragment-based QSAR model finds key substructures linked to potent DPP-4 inhibition, including 2-cyanopyrrolidine, 3-amino tetrahydropyran, and difluoro phenyl groups. D0010 (3-aminotetrahydropyran fingerprint G10) is the most reactive, while D0094 (difluorophenyl fingerprint G14) is the most stable, with D0012 and D0013 (2-cyanopyrrolidine fingerprints G1, G5) offering a balance between stability and reactivity. In addition, the d4p_v1 tool (https://github.com/Amincheminfom/d4p_v1) reliably distinguishes active and inactive DPP-4i using molecular descriptors derived from input SMILES strings. Therefore, this study not only revealed the chemical space of DPP-4i but also opened up a horizon in developing novel potent DPP-4i for the management of type 2 diabetes mellitus (T2DM) in the future.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70106","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validated Stability-Indicating RP-HPLC Method for Nirmatrelvir in Self-Emulsifying Drug Delivery Systems: Formulation Characterization and Permeability Enhancement 经验证的稳定性指示反相高效液相色谱法用于自乳化给药系统：配方表征和增强渗透性

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-09-22 DOI: 10.1002/ardp.70100

Ravi Patel, Ritu Sharma, Dignesh Khunt, Binit Patel

{"title":"Validated Stability-Indicating RP-HPLC Method for Nirmatrelvir in Self-Emulsifying Drug Delivery Systems: Formulation Characterization and Permeability Enhancement","authors":"Ravi Patel, Ritu Sharma, Dignesh Khunt, Binit Patel","doi":"10.1002/ardp.70100","DOIUrl":"https://doi.org/10.1002/ardp.70100","url":null,"abstract":"<div>\u0000 \u0000 <p>This study presents a novel analytical and formulation strategy to enhance the oral delivery and quality assessment of Nirmatrelvir, a poorly water-soluble antiviral agent. A self-emulsifying drug delivery system (SEDDS) was developed using Labrafac MC 60, ethanol, and Transcutol HP (55:25:20), resulting in a nanoemulsion with a droplet size of 145.23 ± 3.23 nm, low polydispersity index (0.189 ± 0.023), and high transmittance (98.97 ± 0.25%). The formulation exhibited rapid emulsification (< 90 s) and significantly improved permeability, achieving a fivefold increase (Papp: 4.20 × 10<sup>−6</sup> cm/s) across Caco-2 cell monolayers compared to the tablet formulation. A stability-indicating reverse-phase HPLC method was developed using a mobile phase of 5 mM potassium dihydrogen phosphate buffer (pH 4.0) and acetonitrile (40:60, v/v), and validated per ICH Q2(R1) guidelines. The method showed excellent linearity (<i>R</i><sup>2</sup> = 0.9999), accuracy (98.6%–100.2%), precision (%RSD < 0.3%), and robustness. An optimized sample preparation protocol ensured efficient extraction of Nirmatrelvir from the SEDDS matrix with minimal interference. Forced degradation studies under ICH Q1A(R2) demonstrated that Nirmatrelvir remained stable under oxidative (98.44%), thermal (98.45%), and photolytic (98.50%) conditions. Maximum degradation was observed under alkaline stress (20.56% at 0.5 N NaOH), followed by acidic stress (13.53% at 5 N HCl). The major alkaline degradant (Rt 2.7 min) was characterized by LC-TQ/MS (<i>m/z</i> 518.2 [M+H]⁺). The method's sustainability was supported by an AGREE score of 0.64 and a Whiteness score of 85.4, offering a validated platform for routine analysis of Nirmatrelvir in lipid-based formulations.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring Micellar Systems for Intra-Articular Delivery of Vanillic Acid in Management of Osteoarthritis 探索香草酸胶束系统在骨关节炎治疗中的关节内输送。

IF 3.6 3区医学

Archiv der Pharmazie Pub Date : 2025-09-18 DOI: 10.1002/ardp.70099

Shaimaa S. Ibrahim, Hend Abd-allah

引用次数: 0